000112448 001__ 112448
000112448 005__ 20220525091008.0
000112448 0247_ $$2doi$$a10.1186/s13601-020-00349-4
000112448 0248_ $$2sideral$$a128497
000112448 037__ $$aART-2020-128497
000112448 041__ $$aeng
000112448 100__ $$aSánchez-Hernández, M. Cesárea
000112448 245__ $$aValidation of the DECA criteria for allergic conjunctivitis severity and control
000112448 260__ $$c2020
000112448 5060_ $$aAccess copy available to the general public$$fUnrestricted
000112448 5203_ $$aBackground: Allergic conjunctivitis (AC) is usually associated to allergic rhinitis (AR), but the severity and control of ocular symptoms should be assessed independently to improve diagnosis and treatment. The criteria from the Spanish consensus document on allergic conjunctivitis (DECA) aimed to be used as a patient-reported instrument for AC management. Here we validate these criteria for classifying AC severity and defining its control following COSMIN guidelines recommendations. Methods: Patients with moderate or severe AR [reflective total nasal symptom score (rTNSS) score ≥ 8] and concomitant AC were recruited from hospitals in Spain. Patients were classified according to the severity of ocular symptoms as mild, moderate, or severe, and classified with respect to control as controlled and non-controlled, using the DECA criteria. To validate these criteria, comparisons with the validated modified allergic rhinitis and its impact on asthma (mARIA), reflective total ocular symptom score (rTOSS), rhinitis control assessment test (RCAT), ESPRINT-15 questionnaires, a conjunctival hyperemia scale and a visual analogue scale (VAS) for ocular symptoms were performed. Results: A total of 128 patients participated in the validation. Mean age was 34.4 ± 12.1 years; 72.7% were women. The DECA criteria showed a good discriminant validity, reflecting a high capacity to differentiate between mild, moderate, and severe patients, and controlled from uncontrolled patients. A strong association between AC and AR was reflected in the comparison between the DECA and the mARIA criteria (p < 0.0001). The DECA criteria for severity and control presented satisfactory properties for longitudinal validity and responsiveness. Conclusions: Validation of the DECA criteria for severity and control of AC suggested that it can be useful in the evaluation of eye symptoms and follow-up of therapies.
000112448 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000112448 590__ $$a5.871$$b2020
000112448 591__ $$aALLERGY$$b8 / 28 = 0.286$$c2020$$dQ2$$eT1
000112448 592__ $$a0.978$$b2020
000112448 593__ $$aImmunology$$c2020$$dQ2
000112448 593__ $$aPulmonary and Respiratory Medicine$$c2020$$dQ2
000112448 593__ $$aImmunology and Allergy$$c2020$$dQ2
000112448 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000112448 700__ $$aNavarro, Ana M.
000112448 700__ $$0(orcid)0000-0001-8959-6784$$aColás, Carlos$$uUniversidad de Zaragoza
000112448 700__ $$aCuvillo, Alfonso del
000112448 700__ $$aSastre, Joaquín
000112448 700__ $$aMullol, Joaquim
000112448 700__ $$aValero, Antonio
000112448 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000112448 773__ $$g10, 1 (2020), [9 pp.]$$pClin. transl. allergy$$tClinical and translational allergy$$x2045-7022
000112448 8564_ $$s1318559$$uhttps://zaguan.unizar.es/record/112448/files/texto_completo.pdf$$yVersión publicada
000112448 8564_ $$s2625576$$uhttps://zaguan.unizar.es/record/112448/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000112448 909CO $$ooai:zaguan.unizar.es:112448$$particulos$$pdriver
000112448 951__ $$a2022-05-25-08:22:19
000112448 980__ $$aARTICLE